Document is current
Any future updates will be listed below
-
Authors
Barlowe, Trevor S.
Gouker, Lindsey N.
Buse, John B.
Sandler, Robert S.
Dougherty, Michael K.
-
Funding
Funding for this research was provided by:
National Institutes of Health (T32 DK007634)
- License Information
-
More Information
Article History
Accepted: 6 May 2025
First Online: 13 June 2025
Declarations
:
: This author discloses the following: John B. Buse reports research support from Corcept, Dexcom, and Novo Nordisk; consulting fees from Altimmune, Antag, Amgen, ApStem, Aqua Medical, AstraZeneca, Boehringer-Ingelheim, CeQur, Corcept Therapeutics, Dexcom, Eli Lilly, embecta, GentiBio, Glyscend, Insulet, Medtronic MiniMed, Mellitus Health, Metsera, Novo Nordisk, Pendulum Therapeutics, Praetego, Stability Health, Tandem, Terns Inc, Vertex, Zealand; stock options from Glyscend, Mellitus Health, Metsera, Pendulum Therapeutics, Praetego, and Stability Health. The remaining authors disclose no conflicts.
: John B. Buse reports research support from Corcept, Dexcom, and Novo Nordisk; consulting fees from Altimmune, Antag, Amgen, ApStem, Aqua Medical, AstraZeneca, Boehringer-Ingelheim, CeQur, Corcept Therapeutics, Dexcom, Eli Lilly, embecta, GentiBio, Glyscend, Insulet, Medtronic MiniMed, Mellitus Health, Metsera, Novo Nordisk, Pendulum Therapeutics, Praetego, Stability Health, Tandem, Terns Inc, Vertex, Zealand; stock options from Glyscend, Mellitus Health, Metsera, Pendulum Therapeutics, Praetego, and Stability Health. The remaining authors disclose no conflicts.
